(Q77493118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Pharmacological and clinical profile of anastrozole (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

J Geisler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

M Dowsett

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

49 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

S53-7; discussion S73-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797018%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006000806630

6 December 2019

exact match

0 references

cites work

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006000806630

7 January 2021